1. Introduction {#s0005}
===============

Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder and is characterized by a relapse-remitting course that is caused by recurrent intestinal inflammation [@bib1]. The two major forms of IBD, Crohn\'s disease (CD) and ulcerative colitis (UC), often have an onset during early adulthood and significantly affect the quality of the life [@bib2]. The established high prevalence of IBD population in US and Europa indicate the requirement for an efficient treatment for IBD [@bib2]. However, the existing treatments are mainly focus on relieving of symptoms and are often accompanied with unwanted side effects [@bib3]. To elucidate the disease pathogenesis and develop more efficient treatment, there is growing interest for targeting pattern recognition receptors (PRRs). The unique microenvironment in the gut, where abundant microorganisms co-exist and the microbial-sensing ability of PRRs suggest that PRRs could contribute to both maintaining and breakdown of the intestinal homeostasis [@bib4], [@bib5]. The development of gut dysbiosis and imbalances in host-microbiome interaction has been demonstrated to contribute to the extent, severity and chronicity of intestinal inflammation [@bib2]. Furthermore, an aberrant immune response towards gut bacteria has been suggested to be the major contributor in the inflammatory response of IBD [@bib6].

Toll-Like receptors (TLRs) are possibly the best studied PRRs that sense a broad spectrum of invading pathogens by recognize pathogen-associated molecular patterns (PAMPs), unique molecules on these pathogens [@bib7]. Up to date, 13 TLRs have been discovered, from which TLR1-9 are conserved in both human and mouse. Based on the location, these TLRs can be divided into two groups; receptors expressed on the cell surface (TLR1, TLR2, TLR6, TLR4 and TLR5) and intracellular receptors (TLR3, TLR7, TLR8 and TLR9) [@bib7]. To recognize the specific ligand, the TLRs form functional mono-dimers or a functional complex with other component such as MD-2 (for TLR4), except TLR1, TLR2 and TLR6 [@bib7]. Both TLR1 and TLR6 form functional hetero-dimer complex with TLR2 to recognize triacyl- or diacyl-lipopeptides from bacteria, respectively [@bib8]. Upon activation by specific ligand derived from bacteria, fungi, parasites or virus, they will induce innate immune response and strength adaptive immune response to provide protection against pathogens [@bib9]. However, unregulated activation of TLRs could lead to extensive and chronic inflammation, which results in inflammatory disease such as IBD [@bib4], [@bib10]. In agreement with this hypothesis, increased expression of TLRs such as TLR2, TLR3 and TLR4, are found in the colon of IBD patient [@bib11], [@bib12]. In addition, an association was found between the polymorphism of TLRs and the susceptibility of IBD development [@bib13], [@bib14], [@bib15].

Nucleotide-binding oligomerization domain-containing protein (human: NOD; mice Nod) is another PRR family. Two member of this PRR group, NOD1 and NOD2 are located exclusively intracellular and able to detect peptidoglycan, a cell wall component on bacteria [@bib16]. There has been great interest in studying the role of NOD2 and its related receptor NOD1 in IBD development, because NOD2 encoding gene *NOD2* is the first gene that has been directly associated with CD and confer great risk for the development of IBD [@bib17], [@bib18]. The CD risk variant *NOD2* gene causes 'loss of function' resulting in reduced autophagy induction which result in reduced bactria killing and impaired antigen presenting, which could be the trigger to the development of IBD [@bib19].

Experimental animal models have been used to study the pathology of the IBD and clarify the underlying mechanisms [@bib20]. Among these animal models, DSS-induced colitis in mice is most commonly used model to investigate IBD-like colitis due to its simplicity and the ability to induce predictable intestinal inflammation [@bib21], [@bib22]. While single DSS exposure induces colitis modeling acute injury and repair mechanism, repeated DSS exposure cycles interspersed with recovery period mimic the chronic nature of IBD [@bib23], [@bib24].

In our previous study, we have illustrated the colonic expression pattern of PRRs and the T-helper (Th) cell response in mice using a DSS-induced acute colitis model. To extent our knowledge of the expression of these PRRs and activated immune response during chronic colitis, the mRNA expression of these PRRs in the colon during chronic colitis was determined after repeated DSS exposure. In addition, the T cell development during the chronic colitis was monitored by measuring the mRNA expression of T cell-associated master transcription factors and cytokines.

2. Materials and methods {#s0010}
========================

2.1. Animals {#s0015}
------------

Female C57BL/6 mice were purchased from Charles River Laboratories (Maastricht, the Netherlands). All mice were used at 8--12 weeks of age and were housed under standard conditions in the animal facilities at Utrecht University. All animal experiments were approved by and were in accordance with the guidelines of the Dutch Experimental Animal Commission. The approval document is encoded with 2008.II.03.030.

2.2. Experimental colitis {#s0020}
-------------------------

Chronic colitis was induced in groups of 6 mice by administration of 3 cycles 1.5% DSS to the drinking water of the mice for 6 days with a rest period of 10 days. Colitis development was monitored by measuring the bodyweight and scoring the feces condition during the experiment and measuring the colon length/weight ration after sacrificing the mice on the end of each DSS treatment cycle (day 7, day 23 and day 39). The feces condition assessment was started from experimental day 5 until the end of the experiment (day 39). The feces condition score was determined from two parameters: stool consistency (0 = normal, 1 = soft with normal form, 2 = loss of form/diarrhea) and fecal bleeding (0 = no blood, 1 = blood observation using Colo-rectal Test kit (Axon Lab AG, Germany), 2 = blood observation without test).

2.3. Histological evaluation of colon damage and immunohistochemical staining {#s0025}
-----------------------------------------------------------------------------

After sacrificing the mice on the end of each DSS treatment cycle (day 7, day 23 and day 39), colons (n = 3) were taken out for histological evaluation and immunohistochemical staining. The colon was opened longitudinally; half of each colon was washed in the phosphate buffered saline (PBS) and placed on a piece of blotting paper. After fixing in 10% formalin for 24 h, colons were paraffin-embedded as swiss-roles and sectioned (5 µm). Two researchers assessed general inflammatory features blindly after staining sections with hematoxylin and eosin according the assessment system described before [@bib25]. Briefly, the histological assessments included four pathological criteria: the extent of cellular infiltration (0: no infiltration, 1: infiltration between the crypts, 2: infiltration in the submucosa, 3: infiltration in the muscularis externa, 4: infiltration in entire tissue); cover area of cellular infiltration in the region (0: no infiltration, 1: \< 25%, 2: 25--50%, 3: 50--75%, 4: \>75%); loss of crypts (0: no damage, 1: 30% shortening of crypts, 2: 65% shorting of crypts, 3: total loss of crypts, 4: loss of entire epithelial layer); extent of crypts loss in the region (0: no crypt loss, 1: \< 25%, 2: 25--50%, 3: 50--75%, 4: \> 75%). Individual scores were obtained for the whole colon from caecum to anus by two researchers who did not know the origin of the sample.

Immunohistochemistry was employed to determine the Ly-6B.2+ cells (neutrophils & some activated macrophages) and Foxp3+ cells. The sections were subjected to a heat-induced epitope retrieval step. Slides were washed with PBS and blocked with rabbit or goat serum before an overnight incubation (4 °C) with primary antibodies against Ly-6B.2 (AbD Serotec, Dusseldorf, Germany) or Foxp3 (eBioscience San Diego, CA USA). For detection, biotinylated goat anti-rat (Dako, Glostrup, DK) secondary antibodies were administered followed by incubation with peroxidase-labeled streptavidin (Vectastain EliteABC kit, Vector, Burlingame, CA USA). The peroxidase activity was visualized using the substrate, DAB (Sigma, Gillingham, UK). The cell nuclei were visualized by a short incubation with Mayer\'s hematoxylin (Klinipath, Duiven, the Netherlands). Background staining was determined by substituting the primary antibody with a rat IgG isotype control (Abcam, Cambrige, UK, [Fig. S6](#s0115){ref-type="sec"}). The neutrophil infiltration score and Foxp3+ cell score were determined using the following criteria: the extent of Ly6B.2+ or Foxp3+ cellular infiltration (0: no infiltration, 1: infiltration between the crypts, 2: infiltration in the submucosa, 3: infiltration in the muscularis externa, 4: infiltration in entire tissue); cover area of cellular infiltration in the region (0: no infiltration, 1: \< 25%, 2: 25--50%, 3: 50--75%, 4: \> 75%). Individual scores for Ly6B.2+ cellular infiltration were obtained for the whole colon from caecum to anus. Individual scores for Foxp3+ cellular infiltration were tallied for the proximal colon (characterized by bulges in the colon wall) and the distal colon (the region starting from end of proximal portion stretching to the anus). Scoring was performed by two researchers who did not know the origin of the sample

2.4. Assessment of myeloperoxidase concentration in the colon tissue {#s0030}
--------------------------------------------------------------------

After sacrificing the mice, colons (n = 3) were taken out for myeloperoxidase (MPO) concentration assessment, marker for neutrophils. The colon was opened longitudinally; half of each colon was separated into proximal colon (characterized by bulges in the colon wall) and distal colon (the region starting from end of proximal portion stretching to the anus). Subsequently, the colons pieces were transferred into RIPA buffer (Thermo Scientific, Rockford, IL USA) and homogenized using a Precellys®24-Dual homogenizer (Precellys, Villeurbanne, France). The homogenates were centrifuged at 14,000 rpm for 10 min at 4 °C and the MPO concentration in the supernatant was measured using an ELISA kit according to the manufacturer\'s protocol (Hycult biotech, Uden, the Netherlands).

2.5. mRNA expression analysis {#s0035}
-----------------------------

After sacrificing the mice, colons (n = 6) were taken out for gene expression analysis. The colon was opened longitudinally and the proximal colon was distinct from the distal colon by its specific structure (bulges in the colon wall). The total RNA was isolated using the RNAeasy kit (Qiagen, Germantown, MD USA) and, subsequently, reverse transcribed into cDNA using the iScript cDNA sythesis kit (BioRad, Hercules, CA USA). Real-time PCR was performed using iQ SYBR Green super mix kit (BioRad, Hercules, CA USA) with the CFX 96 Real-time system (BioRad, Hercules, CA USA) and the relative mRNA expression values were calculated using Bio-Rad CFX manager V1.6. The sequence of specific primers for *Nod1* and *Nod2*, *Tlrs*, T cell transcription factor genes, and the gene for the household protein ribosomal protein S13 (*Rps13*) are listed in [Table 1](#t0005){ref-type="table"}. The primers for the cytokines: tumor necrosis factor-α (*Tnf),* interleukin-1β (*Il-1beta), Il-6,* monocyte chemotactic protein-1 (*Ccl-2),* interferon-γ (*Ifn-gamma), Il-12p35, Il-4, Il-5, Il-13, Il-23p19, Il-17, Il-10* and transforming growth factor β (*Tgf-beta)* were purchased from SABioscience (Frederick, MD USA). The final data for the target samples were normalized against the internal control *Rps13*.Table 1qPCR primer sequence.Table 1**Primer Sequence 5′→3′Forward primerReverse primer***Tlr1*GGTGTTAGGAGATGCTTATGGGGGATGTTAGACAGTTCCAAACCGA*Tlr2*CCAGACACTGGGGGTAACATCCGGATCGACTTTAGACTTTGGG*Tlr3*GGGGTCCAACTGGAGAACCTCCGGGGAGAACTCTTTAAGTGG*Tlr4*GCCTTTCAGGGAATTAAGCTCCAGATCAACCGATGGACGTGTAA*Tlr5*TCAGACGGCAGGATAGCCTTTAATGGTCAAGTTAGCATACTGGG*Tlr6*GACTCTCCCACAACAGGATACGTCAGGTTGCCAAATTCCTTACAC*Tlr7*TCTTACCCTTACCATCAACCACACCCCAGTAGAACAGGTACACA*Tlr8*GGCACAACTCCCTTGTGATTCATTTGGGTGCTGTTGTTTG*Tlr9*ACTCCGACTTCGTCCACCTGGCTCAATGGTCATGTGGCA*Nod1*GAAGGCACCCCATTGGGTTAATCTCTGCATCTTCGGCTGA*Nod2*CCGCTTTCTACTTGGCTGTCGTGATTTGCAGGTTGTGTGG*Tbet*GCCAGCCAAACAGAGAAGACAAATGTGCACCCTTCAAACC*Gata3*GCGGTACCTGTCTTTTTCGTCACACAGGGGCTAACAGTCA*Foxp3*CACTGGGCTTCTGGGTATGTAGACAGGCCAGGGGATAGTT*Rorc*TGCAAGACTCATCGACAAGGAGGGGATTCAACATCAGTGC*Rps13*GTCCGAAAGCACCTTGAGAGAGCAGAGGCTGTGGATGACT

2.6. Statistical analysis {#s0040}
-------------------------

Means with SEM are represented in each graph. Statistical analysis was performed using GraphPad Prism version 6.0 for windows (GraphPad Software, San Diego, CA USA). P-values were calculated using either the two-way ANOVA followed by Bonferroni post-tests or a Mann-Whitney test. P-values considered as significant are indicated as \*\*\* \< 0.001, \*\* \< 0.01, and \* \< 0.05. ^a^ p \< 0.05 cycle 2 and cycle 3 control mice compare to cycle 1 control mice. ^b^ p \< 0.05 DSS-treated mice compare to control mice after each DSS treatment cycle. ^c^ p \< 0.05 cycle 2 and cycle 3 DSS-treated mice compare to cycle 1 DSS-treated mice ^d^ p \< 0.05 cycle 3 DSS-treated mice compare to cycle 2 DSS-treated mice.

3. Results {#s0045}
==========

3.1. Repeated DSS treatment induces features of chronic colitis {#s0050}
---------------------------------------------------------------

In a previous study, we have induced an acute colitis by adding 1.5% DSS into drinking water of mice for 6 days and found decreased bodyweight and increased feces score [@bib25]. In the current study, we assessed the bodyweight and fecal phenotype changes of mice undergoing repeated DSS treatments. Acute colitis was accompanied with a decreased bodyweight and increased feces score. After repeated DSS treatments, there were no longer inductions of major bodyweight loss as observed after the first DSS treatment cycle ([Fig. 1](#f0005){ref-type="fig"}A). During and after all three cycles of DSS treatment increased feces scores were found, although a less extended increase and faster recovery rate were observed during and after second and third DSS treatment ([Fig. 1](#f0005){ref-type="fig"}B). After sacrificing the mice, the colon length and weight were measured. There was a decreased colon length/weight ratio after each DSS treatment cycle as compare to healthy mice: this ratio further decreased as the DSS treatment cycle progressed ([Fig. 1](#f0005){ref-type="fig"}C).Fig. 1**An increased feces score was found after each DSS treatment, while bodyweight loss was only found after acute DSS treatment.** A) The bodyweight changes of control and DSS-treated mice during repeated DSS treatment are illustrated in the figure. B) The increased fecal scores of DSS-treated mice as compared to control mice after the first DSS treatment until end of the experiment are shown (n = 18 during cycle 1 DSS treatment, n = 12 during cycle 2 DSS-treatment and n = 6 cycle 3 DSS treatment). C) The colon length (cm) /weight (mg) ratio was determined (n = 6 per group). All results are expressed as + SEM, \* indicates significant different between control and DSS-treated group. \# Indicates significant different between the DSS-treatment cycles ^\#\#,\ \*\*^ P \< 0.01, ^\*\*\*^ P \< 0.001.Fig. 1

To determine the extent of the inflammation, colonic histological score including tissue damage and cellular infiltration was accessed. The tissue damage and cellular infiltrations were observed in the colon of DSS-treated mice, predominantly in the distal part, after each DSS treatment ([Fig. 2](#f0010){ref-type="fig"}). The MPO levels and Ly-6B.2 expressing cells in colon were analyzed to determine the infiltration of neutrophil cells. MPO is abundantly expressed in neutrophil granulocytes [@bib26] and is frequently used as marker of neutrophil infiltration, while Ly-6B.2 expression is particularly high on the surface of neutrophils and some inflammatory macrophages [@bib27]. An increased expression of MPO was found in both proximal and distal part of the colon isolated from DSS-treated mice as compare to healthy control mice after each DSS treatment cycle ([Fig. 3](#f0015){ref-type="fig"}A). This result indicates an increased amount of neutrophils in the colon of DSS-treated mice. The increased score of Ly-6B.2 expressing cell in the colon of DSS-treated mice supports this finding ([Fig. 3](#f0015){ref-type="fig"}B-D). In addition, a significant increase of neutrophil score was found after second DSS treatment as compared with first and third DSS treatment cycle ([Fig. 3](#f0015){ref-type="fig"}B-D).Fig. 2**DSS treatment induces damage and cellular infiltration in the colon.** Colons were collected for histological assessment as described in material and methods. A) Colonic histological score and B) representative histology staining photos of the colons derived from control or DSS-treated mice after each DSS treatment cycle are shown (n = 3 per group).Fig. 2Fig. 3**DSS treatment induces neutrophil influx in the colon.** Colons were collected for A) MPO concentration measurement in the proximal and distal colon and B) immunohistochemical assessment of Ly-6b+ cells. Representative histochemical staining picture of Ly-6b+ cells in the colons of C) control and D) DSS-treated mice during each DSS treatment cycle are shown. All results are expressed as + SEM n = 3, \* indicates the significant different between control and DSS-treated group. \# indicates the significant different between the DSS-treatment cycles ^\#,\ \*^ P \< 0.05, ^\#\#,\ \*\*^ P \< 0.01, ^\*\*\*^ P \< 0.001.Fig. 3

Taken together, these results indicate that repeated DSS treatments result in chronic colitis accompanied by profound neutrophil infiltration.

3.2. mRNA expression of both *Nod 1* and *Nod 2* was increased during acute colitis, while different mRNA expression patterns were found during the chronic phase {#s0055}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the mRNA expression of *Nod1* and *Nod2* during the DSS induced chronic colitis, the specific mRNA expression in both proximal and distal part of the colon isolated from either healthy or DSS-treated mice was determined ([Fig. 4](#f0020){ref-type="fig"}). The DSS induced transcriptional modulation was mainly found in the distal part of the colon ([Fig. 4](#f0020){ref-type="fig"}B). In the proximal part of the colon, there was no significant change of mRNA expression between healthy and DSS-treated mice, except a decreased *Nod1* mRNA expression after second DSS treatment ([Fig. 4](#f0020){ref-type="fig"}A). In the distal part of the colon, there were increased mRNA expressions of both *Nod1* and *Nod2* during acute colitis, although the expression of *Nod1* did not reach significance ([Fig. 4](#f0020){ref-type="fig"}B). During chronic colitis, the mRNA expression of *Nod2* was significantly increased after second DSS treatment and an enhanced trend was observed after third DSS treatment ([Fig. 4](#f0020){ref-type="fig"}B). In contrast, there was a significantly reduced mRNA expression of *Nod1* during after the second DSS treatment ([Fig. 4](#f0020){ref-type="fig"}B)Fig. 4**Acute DSS treatment increases both the*****Nod 1*****and*****Nod 2*****expression, while repeated DSS treatment induces different effect between Nod1 and Nod2 expression**. Colons were collected for the mRNA expression assessment of PRR. The mRNA expressions of *Nod 1* and *Nod 2* in the A) proximal -- and B) distal part of the colon are shown. All results are expressed as + SEM, n = 6. ^\*\*^ P \< 0.001.Fig. 4

3.3. *Tlr5* mRNA expression is the only extracellular *Tlr* that is structurally modified after every DSS treatments {#s0060}
--------------------------------------------------------------------------------------------------------------------

To further investigate the mRNA expression of PRRs during the DSS induced chronic colitis, we have accessed the mRNA expression of TLRs located on the cell surface (*Tlr1, Tlr2, Tlr6, Tlr4 and Tlr5*) in both proximal and distal part of the colon isolated from either healthy or DSS-treated mice ([Fig. 5](#f0025){ref-type="fig"}). The DSS treatment induced modulatory effects on the transcription of bacterial recognizing TLRs were mainly found in the distal part of colon ([Fig. 5](#f0025){ref-type="fig"}B). In the proximal part of colon, there was no significant change of the mRNA expressions, though a tendency of an increased *Tlr1* expression after third DSS treatment decreased mRNA expression of *Tlr5* after first DSS treatment and *Tlr6* after second DSS treatment was observed ([Fig. 5](#f0025){ref-type="fig"}A). In the distal part of colon, the acute colitis was accompanied with significant increased mRNA expressions of *Tlr2, Tlr6* and *Tlr4*. The mRNA expression of *Tlr1* was unchanged during acute colitis, whereas a significant reduced expression of *Tlr5* was observed ([Fig. 5](#f0025){ref-type="fig"}B). During chronic colitis, *Tlr1* mRNA expression remained unchanged. Interestingly, the significant increased expression of *Tlr2* and *Tlr6* mRNA during the acute colitis was profoundly reduced after repeated DSS treatment, though *Tlr2* tended to be increased after the second DSS treatment. In addition, a significant increased *Tlr4* mRNA expression was found after third DSS treatment, but not during second DSS treatment. *Tlr5* is the only extracellular TLR that was modulated in a similar way after each DSS treatment: the mRNA expression of *Tlr5* was significantly reduced after each DSS treatment ([Fig. 5](#f0025){ref-type="fig"}B).Fig. 5**The mRNA expression of bacterial PAMP recognizing*****Tlrs*****is differently modulated by repeated DSS treatment.** Colons were collected for mRNA expression assessment of PRR. The mRNA expressions of *Tlr 1*, *Tlr2*, *Tlr6, Tlr4, Tlr5,* and *Tlr9* in the A) proximal- and B) distal part of the colon are shown. All results are expressed as + SEM, n = 6. ^\*^ P \< 0.05, ^\*\*^ P \< 0.01, ^\*\*\*^ P \< 0.001.Fig. 5

3.4. *TLR9* mRNA expression is the only intracellular *Tlr* that is structurally modified after every DSS treatment {#s0065}
-------------------------------------------------------------------------------------------------------------------

Intracellular TLRs comprise TLR3, TLR7 and TLR8 that recognize single- and double-strand virus RNA (dsRNA) and TLR9 that recognize CpG-rich DNA derived from virus and bacteria [@bib28], [@bib29], [@bib30].

To determine the mRNA expression of this subfamily of TLR during the DSS-induced chronic colitis, the specific mRNA expression was examined in both proximal and distal part of the colon after each DSS treatment cycle ([Fig. 6](#f0030){ref-type="fig"}). In the proximal part of the colon, only *Tlr8* showed a significantly increased mRNA expression during acute colitis. A significantly decreased mRNA expression of *Tlr7* was observed during chronic colitis after the second DSS-treatment ([Fig. 6](#f0030){ref-type="fig"}A). In the distal part of the colon, the mRNA expression of all intracellular *Tlrs* was significantly increased during acute colitis and returned to basal expression levels after chronic DSS treatment, except for *Tlr3* and *Tlr9* During chronic colitis, *Tlr3* mRNA expression was significantly increased after the third DSS, while the mRNA of *Tlr9* was elevated after each DSS treatment ([Fig. 6](#f0030){ref-type="fig"}B).Fig. 6**Repeated DSS treatment increases mRNA expression of viral-associated*****Tlrs*****in the distal colon.** Colons were collected for mRNA expression assessment of PRR. The mRNA expressions of *Tlr3*, *Tlr7* and *Tlr8* in both A) proximal- and B) distal part of the colon are shown. All results are expressed as + SEM, n = 6. ^\*^ P \< 0.05, ^\*\*^ P \< 0.01.Fig. 6

3.5. mRNA expression of pro-inflammatory cytokines is significantly increased during acute and chronic colitis {#s0070}
--------------------------------------------------------------------------------------------------------------

In a previous study, we have demonstrated that acute colitis is accompanied with increased mRNA expression of pro-inflammatory cytokines [@bib25]. To investigate whether the increase also persists during the chronic colitis, mRNA expression of pro-inflammatory cytokines was explored ([Table 2](#t0010){ref-type="table"}). A significantly increased mRNA expression of *Tnfα, Ccl2, Il1β* and *Il6* was observed in both the proximal and distal part of the colon during acute colitis. In addition, a similar increased mRNA expression of these cytokines was observed during chronic colitis, although the expression of *Ccl2* in the proximal part of the colon did not reach significance after the second DSS treatment.Table 2DSS treatment increased mRNA expression of pro-inflammatory cytokines.Table 2**Pro-inflammatory cytokines*****Tnfα***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.06 ± 0.020.42 ± 0.1[\*\*](#tbl2fnStarStar){ref-type="table-fn"}0.03 ± 0.011.01 ± 0.16[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}Cycle 20.16 ± 0.050.68 ± 0.16[\*](#t0010fna){ref-type="table-fn"}0.08 ± 0.030.83 ± 0.08[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}Cycle 30.16 ± 0.030.87 ± 0.28[\*\*](#tbl2fnStarStar){ref-type="table-fn"}0.25 ± 0.141.15 ± 0.15[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}      ***Ccl2***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.01 ± 00.26 ± 0.08[\*\*](#tbl2fnStarStar){ref-type="table-fn"}0.02 ± 01.15 ± 0.25[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}Cycle 20.13 ± 0.030.25 ± 0.090.14 ± 0.050.72 ± 0.18[\*](#t0010fna){ref-type="table-fn"}Cycle 30.14 ± 0.040.62 ± 0.33[\*](#t0010fna){ref-type="table-fn"}0.17 ± 0.071.17 ± 0.1[\*\*\*](#tbl2fnStarStarStar){ref-type="table-fn"}      ***Il6***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.01 ± 0.010.45 ± 0.2[\*\*](#tbl2fnStarStar){ref-type="table-fn"}0.01 ± 01.09 ± 0.37[\*\*](#tbl2fnStarStar){ref-type="table-fn"}Cycle 20.08 ± 0.010.28 ± 0.04[\*\*](#tbl2fnStarStar){ref-type="table-fn"}0.07 ± 0.010.78 ± 0.23[\*\*](#tbl2fnStarStar){ref-type="table-fn"}Cycle 30.04 ± 0.010.73 ± 0.36[\*](#t0010fna){ref-type="table-fn"}0.03 ± 01.02 ± 0.22[\*\*](#tbl2fnStarStar){ref-type="table-fn"}      ***Il1β***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.01 ± 00.51 ± 0.18[\*\*](#tbl2fnStarStar){ref-type="table-fn"}0.01 ± 01.40 ± 0.43[\*\*](#tbl2fnStarStar){ref-type="table-fn"}Cycle 20.01 ± 00.15 ± 0.02[\*\*](#tbl2fnStarStar){ref-type="table-fn"}0.01 ± 00.68 ± 0.21[\*](#t0010fna){ref-type="table-fn"}Cycle 30.02 ± 00.57 ± 0.26[\*](#t0010fna){ref-type="table-fn"}0.02 ± 01.15 ± 0.17[\*\*](#tbl2fnStarStar){ref-type="table-fn"}[^1][^2][^3][^4]

3.6. Chronic colitis is accompanied with an increased mRNA expression of Th1 cell-associated transcription factors and cytokines {#s0075}
--------------------------------------------------------------------------------------------------------------------------------

Next, we investigate the mRNA expression of Th cell-associated transcription factors and cytokines during the DSS-induced chronic colitis ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}). To accesses the contribution of the Th1 cell response, mRNA expression of *Tbet, Ifnγ* and *Il12* was explored ([Table 3](#t0015){ref-type="table"}). In the proximal part of the colon, there was no significant difference of *Tbet* mRNA expression between healthy and DSS-treated mice, whereas an increased mRNA expression of *Ifnγ* was observed in DSS-treated mice during acute colitis as well as chronic colitis, though the expression after third DSS treatment did not reach significance. In contrast to *Ifnγ*, there was a significant decrease in *Il12* mRNA expression after second DSS. In the distal part of the colon, increased mRNA expression of Th1 cell transcription factor *Tbet* as well as Th1 cell-associated cytokines *Ifnγ* and *Il12* was found during both acute and chronic DSS colitis, though the mRNA expression of *Il12* after third DSS treatment did not reach significance.Table 3DSS treatment increased the transcripts associated with Th1 response.Table 3**Th1-associated transcription factor and cytokines*****Tbet***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.63 ± 0.220.51 ± 0.120.38 ± 0.081.52 ± 0.24[\*\*](#tbl3fnStarStar){ref-type="table-fn"}Cycle 21.45 ± 0.311.76 ± 0.290.48 ± 0.091.65 ± 0.39[\*\*](#tbl3fnStarStar){ref-type="table-fn"}Cycle 31.16 ± 0.221.20 ± 0.030.40 ± 0.111.27 ± 0.11[\*\*](#tbl3fnStarStar){ref-type="table-fn"}      ***Ifnγ***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.01 ± 00.19 ± 0.11[\*](#t0015fna){ref-type="table-fn"}0.01 ± 00.82 ± 0.13[\*](#t0015fna){ref-type="table-fn"}Cycle 20.05 ± 0.010.31 ± 0.11[\*](#t0015fna){ref-type="table-fn"}0.03 ± 0.010.67 ± 0.18[\*\*\*](#tbl3fnStarStarStar){ref-type="table-fn"}Cycle 30.04 ± 0.020.43 ± 0.16^ρ\ =\ 0.058^0.05 ± 0.040.92 ± 0.12[\*\*\*](#tbl3fnStarStarStar){ref-type="table-fn"}      ***Il12***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.20 ± 0.070.31 ± 0.090.30 ± 0.091.23 ± 0.18[\*\*\*](#tbl3fnStarStarStar){ref-type="table-fn"}Cycle 20.52 ± 0.050.31 ± 0.05[\*](#t0015fna){ref-type="table-fn"}0.36 ± 0.030.89 ± 0.18[\*](#t0015fna){ref-type="table-fn"}Cycle 30.88 ± 0.180.64 ± 0.180.74 ± 0.131.03 ± 0.11[^5][^6][^7][^8]Table 4While increased Th2 transcription factor was found after each DSS treatment cycle, only *Il4* was increased after acute DSS treatment.Table 4**Th2-associated transcription factor and cytokines*****Gata3***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.20 ± 0.030.90 ± 0.28[\*](#t0020fna){ref-type="table-fn"}0.24 ± 0.050.96 ± 0.17[\*\*](#tbl4fnStarStar){ref-type="table-fn"}Cycle 20.35 ± 0.051.66 ± 0.27[\*\*\*](#tbl4fnStarStarStar){ref-type="table-fn"}0.24 ± 0.061.06 ± 0.24[\*](#t0020fna){ref-type="table-fn"}Cycle 30.21 ± 0.031.51 ± 0.3[\*\*\*](#tbl4fnStarStarStar){ref-type="table-fn"}0.12 ± 0.021.23 ± 0.51[\*\*](#tbl4fnStarStar){ref-type="table-fn"}      ***Il4***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.37 ± 0.030.27 ± 0.060.47 ± 0.080.87 ± 0.13[\*](#t0020fna){ref-type="table-fn"}Cycle 20.90 ± 0.21.02 ± 0.300.68 ± 0.10.49 ± 0.13Cycle 31.29 ± 0.220.63 ± 0.08[\*](#t0020fna){ref-type="table-fn"}0.81 ± 0.140.57 ± 0.04      ***Il5***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.13 ± 0.060.04 ± 0.020.13 ± 0.070.13 ± 0.08Cycle 20.77 ± 0.230.57 ± 0.230.59 ± 0.110.35 ± 0.13Cycle 30.93 ± 0.120.58 ± 0.12^ρ\ =\ 0.082^0.76 ± 0.130.31 ± 0.05[\*](#t0020fna){ref-type="table-fn"}      ***Il13***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.98 ± 0.290.51 ± 0.10.79 ± 0.121.03 ± 0.13Cycle 20.96 ± 0.211.11 ± 0.460.66 ± 0.160.71 ± 0.16Cycle 31.21 ± 0.191.27 ± 0.280.82 ± 0.20.87 ± 0.14[^9][^10][^11][^12]Table 5Increased mRNA expression of *Il17*, but decreased of Th17 associated transcription factors were found after each DSS treatment cycle, *Il23* was only increased after acute DSS treatment.Table 5**Th17-associated transcription factor and cytokines*****Rorc***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.77 ± 0.140.49 ± 0.020.95 ± 0.050.39 ± 0.08[\*\*\*](#tbl5fnStarStarStar){ref-type="table-fn"}Cycle 21.13 ± 0.281.03 ± 0,230.94 ± 0.120.62 ± 0.1^ρ\ =\ 0.089^Cycle 30.92 ± 0.110.98 ± 0.160.93 ± 0.100.63 ± 0.08[\*](#t0025fna){ref-type="table-fn"}      ***Il23***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.39 ± 0.170.54 ± 0.190.44 ± 0.191.19 ± 0.23[\*\*](#tbl5fnStarStar){ref-type="table-fn"}Cycle 20.73 ± 0.160.61 ± 0.100.84 ± 0.070.70 ± 0.09Cycle 30.64 ± 0.130.96 ± 0.240.85 ± 0.140.85 ± 0.05      ***Il17***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.02 ± 00.21 ± 0.080.02 ± 01.02 ± 0.19[\*\*\*](#tbl5fnStarStarStar){ref-type="table-fn"}Cycle 20.05 ± 0.020.28 ± 0.070.04 ± 0.020.55 ± 0.2[\*](#t0025fna){ref-type="table-fn"}Cycle 30.06 ± 0.030.85 ± 0.480.05 ± 0.031.00 ± 0.18[\*\*\*](#tbl5fnStarStarStar){ref-type="table-fn"}[^13][^14][^15][^16]

3.7. mRNA encoding Th2 cell-associated cytokines play a less important role during chronic colitis {#s0080}
--------------------------------------------------------------------------------------------------

To examine the involvement of the Th2 cell response, mRNA expression of *Gata3, Il4, Il5* and *Il13* was determined ([Table 4](#t0020){ref-type="table"}). There was a significant increased mRNA expression of Th2 cell transcription factor *Gata3* in both the proximal and the distal part of colon during acute as well as chronic colitis. Interestingly, there was no significant increase in mRNA expression of the Th2 cell-associated cytokines, except *Il4* expression in the distal colon during acute colitis. A significant decreased mRNA expression of *Il4* in the proximal part of colon and *Il5* in the distal part of colon was observed during chronic colitis after the third DSS treatment.

3.8. Chronic colitis was associated with increased transcript of *Il17* {#s0085}
-----------------------------------------------------------------------

In contrast to Th1 and Th2 cell transcription factors, the transcription factor of Th17 cells, *Rorc* was significantly reduced in the distal part of colon during acute colitis. In addition, the expression remained low during the chronic colitis as compared to the expression in the colon of healthy mice, although it did not reach the significance after the second DSS treatment ([Table 5](#t0025){ref-type="table"}). There was significant sustainable increase in *Il17* mRNA expressions in both the parts of the colon during chronic colitis. In addition, in the distal part of colon, a significant increased *Il23* mRNA expression was observed only during the acute colitis.

3.9. Chronic colitis increased the mRNA expression of *Il10* and enhances the number of Foxp3+ cells in the colon {#s0090}
-----------------------------------------------------------------------------------------------------------------

To determine the contribution of Treg cell-mediated responses, mRNA expression of *Foxp3*, *Tgfβ* and *Il10* was explored ([Table 6](#t0030){ref-type="table"}). Although there was no change of the Foxp3 mRNA expression between healthy and DSS-treated mice, a significant increased *Tgfβ* mRNA expression was found in the distal part of colon during acute colitis, which returned to basal levels after three cycles of DSS treatment. Furthermore, there was a significant increased mRNA expression of Il10 in the distal colon during both acute and chronic colitis, though the expression after the third DSS treatment cycle did not reach significance.Table 6Increased *Il10* mRNA expression was found after each DSS treatment cycle, while *Tgfβ* was only increased after acute DSS treatment.Table 6**Treg-associated transcription factor and cytokines*****Foxp3***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.51 ± 0.150.38 ± 0.30.70 ± 0.140.83 ± 0.07Cycle 21.07 ± 0.10.90 ± 0.140.80 ± 0.070.97 ± 0.09Cycle 31.24 ± 0.350.87 ± 0.280.72 ± 0.11.03 ± 0.11^ρ\ =\ 0.082^      ***Tgfβ***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.41 ± 0.050.41 ± 0.080.61 ± 0.091.42 ± 0.19[\*\*\*](#tbl6fnStarStarStar){ref-type="table-fn"}Cycle 20.50 ± 0.050.34 ± 0.040.57 ± 0.070.80 ± 0.13Cycle 30.68 ± 0.060.54 ± 0.090.75 ± 0.090.84 ± 0.22      ***Il10***Proximal colonDistal colonControl miceDSS-treated miceControl miceDSS-treated miceCycle 10.14 ± 0.040.18 ± 0.040.17 ± 0.050.78 ± 0.10[\*\*](#tbl6fnStarStar){ref-type="table-fn"}Cycle 20.49 ± 0.060.45 ± 0.070.53 ± 0.101.01 ± 0.16[\*](#t0030fn9999){ref-type="table-fn"}Cycle 30.58 ± 0.090.54 ± 0.130.50 ± 0.130.90 ± 0.14^ρ\ =\ 0.076^[^17][^18][^19][^20]

To further analysis the contribution of Treg cells during the chronic colitis, Foxp3+ cells in the colon were examined using histochemistry. There was an increased score of Foxp3+ cell in the colon during chronic colitis, but not in acute colitis ([Fig. 7](#f0035){ref-type="fig"}A-C).Fig. 7**Increased histological score of Foxp3+ cells after each DSS treatment cycle.** Colons were collected for A) immunohistochemical assessment of Foxp3+ cells. Representative histochemical staining pictures of Foxp3+ cells in the colon of B) control and C) DSS-treated mice during each DSS cycle are shown. All results are expressed as + SEM, n = 3.Fig. 7

4. Discussion {#s0095}
=============

In this study, the mRNA expression of colonic PRRs, pro-inflammatory cytokines, T cell-associated transcription factors and cytokines was examined in mice exposed to repeated DSS treatments interspersed with a rest period.

As compared to single DSS exposure-induced colitis study [@bib25], multiple DSS exposure induced chronic colitis in mice shows a higher similarity to IBD that is characterized by remission-relapse course after disease onset [@bib1]. Although we did not found more severe clinical manifestations during the chronic phase of colitis as compared to acute colitis, a gradually decreased colon length and bloody diarrhea were observed during the chronic colitis. The clinical manifestations do not always reflect the severity of intestinal inflammation [@bib22], [@bib26]. Histological analysis shown that chronic inflammation in the colon is characterized by phenotypes such as crypt architecture disarray, pronounced mononuclear leucocytes and neutrophil infiltration, transmural inflammation [@bib26]. All colonic features and the gradually decreased colon length/weight ratio after repeated DSS treatments suggest that our colitis model could be presented as a semi-chronic relapsing colitis model that could provide valuable knowledge to help clarify the development of IBD.

In IBD aberrant and prolonged activation of TLRs can lead to more tissue damage and inflammatory responses [@bib27], [@bib28] resulting in chronic inflammatory disease [@bib11], [@bib12], [@bib29]. Accordingly, the extent and duration of the induction of these PRRs need to be tightly controlled. In this study, the expression of majority of the PRRs, which was enhanced in the inflamed colon region during the acute colitis, including *Tlr2, Tlr3, Tlr4, Tlr6, Tlr7* and *Tlr8,* was not observed after repeated DSS treatments during the chronic colitis, though *Nod2* was increased after the second and third cycle DSS, respectively. Although the exact regulation mechanisms still need to be elucidated, the importance of temporary reduced expression or silencing of these receptors was recognized and negative regulation mechanisms at multiple signaling level were reported [@bib30], [@bib31], [@bib32], [@bib33]. For example, activation of NOD2 decreases TLR2-induced IL12 production [@bib34], while NOD2 signaling can be stimulated by TNFα or IFNγ [@bib35]. Since activation of TLRs lead to production of cytokines including TNFα and IFNγ [@bib36], the increased *Nod2* may be a part of TLR suppression mechanism during the chronic DSS colitis.

In contrast to other *Tlrs*, the colonic mRNA expression of *Tlr5* and *Tlr9* showed a decreased or increased expression trend, respectively, during the chronic phase of colitis. TLR5 recognize bacterial-derived flagellin and is exclusively located on the basolateral [@bib32], [@bib37]. Prolonged exposure of TLR5 to flagellin has been shown to be responsible for flagellin-induced tolerance accompanied by internalization of TLR5 receptors [@bib38]. In addition, IFNγ induces down-regulate *Tlr5* expression in mice colon cells in a dose and time dependent manner [@bib33]. Taken together, the reduced *Tlr5* expression in this study could be the result of combined effects of the overexposure to bacterial-derived flagellin and increased IFNγ expression. As result, the clearance of infiltrated gut bacteria is reduced leading to continuous expression of pro-inflammatory cytokines and chronic intestinal inflammation. This hypothesis is supported by the observation that TLR5-/- mice develop spontaneous colitis [@bib39] and the finding of a strong anti-flagellin antibody response in IBD patients [@bib40], [@bib41].

TLR9 recognize bacterial DNA and activation of TLR9 will induce the expression of pro-inflammatory cytokines such as TNFα, CCL2, IL1β and IL6 [@bib42], [@bib43]. In the colon of chronically DSS exposed mice, the upregulated *Tlr9* expression is associated with enhanced expression of mentioned cytokines mRNA. A recent study demonstrated that Tlr9 signaling is important for the Th1 immune response in mice gut-associated lymphoid tissue (GALT) [@bib44]. In line with these data, enhanced expression of the pro-inflammatory cytokines and Th1 cell-associated cytokine *Ifnγ* were observed in inflamed colon of mice chronically exposed to DSS.

Besides the increased mRNA expression of pro-inflammatory cytokines and *Ifnγ*, only *the Il17* gene showed a persistent increased trend during the chronic colitis. The increased expression of other T cell-associated cytokine genes was abolished after either acute colitis (*Il4, Il23, Tgfβ*) or after repeated DSS treatment cycle (*Il12, Il10, Il*5). These data suggest that the chronic inflammation in this colitis model is mainly directed by the Th1 and Th17 cell immune responses, but not by Th2 cell-mediated immune responses. Furthermore, the decreased IL4 and IL5 mRNA expression could derive from the Th1/Th2 cell paradigm; increased Th1 cell differentiation leads to reduced Th2 cell responses [@bib45], [@bib46]. The increased mRNA expression of Il10 and presence of Foxp3+ cells may indicate to an unsuccessful attempt of Treg cells to control the inflammatory response. Although the mouse Foxp3+ cells are regarded as Treg cells, a subset of Foxp3 expressing CD8+ cytotoxic T cells were found to be involved in early Th17 cell-mediated immune response to enteric pathogen in mice [@bib47]. Furthermore, IL17- and IFNγ secreting Foxp3+ T cells have been demonstrated in peripheral lymph nodes and the spleen [@bib48]. These findings suggest that the Foxp3+ cells observed in this study might not always represent an increased number of Treg cells, but could also be pro-inflammatory cytotoxic T helper cell subpopulations. Further research is needed to confirm this hypothesis.

In this study, we have illustrated the expression profile of colonic PRRs and T cell-associated cytokines during the chronic colitis development using a semi-chronic colitis model that mimics the development of IBD. The current accepted T cell subset associations with the two major forms of IBD are Th1/Th17 cells with CD, while Th2 cell with ulcerative colitis [@bib49], [@bib50]. Human studies have demonstrated the presence of IL-17A in the sera of CD patient and both IFN-γ and IL-17A producing T cells were found [@bib51]. The elevated expression of *Il17* and *Ifnγ* during the chronic DSS colitis suggests this colitis model could provide valuable information for the investigation of the development of CD. In addition, the persistent increased *Tlr9* and decreased *Tlr5* expression during the chronic colitis and their possible involvement in the aberrant immune response suggest that these TLRs could be potential targets for CD treatment.
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[^1]: Colons were collected for examination of the cytokines mRNA expression level. The mRNA expressions of pro-inflammatory cytokines *Tnfα*, *Ccl2, Il6* and *Il1β* in the proximal- and distal part of the colon are shown. All results are expressed as ± SEM, n = 6. ^\*^ indicates the significant different between control and DSS-treated mice.

[^2]: P \< 0.05.

[^3]: P \< 0.01.

[^4]: P \< 0.001.

[^5]: Colons were collected for examination of the mRNA expression level of Th1 transcription factors and associated cytokines. The mRNA expressions of *Tbet*, *Ifnγ* and *Il12* in the proximal- and distal part of the colon are shown. All results are expressed as + SEM, n = 6. ^\*^ indicates the significant different between control and DSS-treated mice.

[^6]: P \< 0.05.

[^7]: P \< 0.01.

[^8]: P \< 0.001.

[^9]: Colons were collected for examination of the mRNA expression level of Th2 transcription factors and associated cytokines. The mRNA expressions of *Gata3*, *Il4*, *Il5* and *Il13* in the proximal- and distal part of the colon are shown. All results are expressed as + SEM, n = 6. ^\*^ indicates the significant different between control and DSS-treated mice.

[^10]: P \< 0.05.

[^11]: P \< 0.01.

[^12]: P \< 0.001.

[^13]: Colons were collected for examination of the mRNA expression level of Th17 transcription factor and associated cytokines. The mRNA expression of Rorc, *Il23* and *Il17* in the proximal- and distal part of the colon are shown. All results are expressed as + SEM, n = 6. ^\*^ indicates the significant different between control and DSS-treated mice.

[^14]: P \< 0.05.

[^15]: P \< 0.01.

[^16]: P \< 0.001.

[^17]: Colons were collected for examination of the mRNA expression level of Treg transcription factor and associated cytokines. The mRNA expression of Foxp3, *Tgfβ* and *Il10* in the proximal- and distal part of the colon are shown. All results are expressed as + SEM, n = 6. ^\*^ Indicates the significant different between control and DSS-treated mice.

[^18]: P \< 0.05.

[^19]: P \< 0.01.

[^20]: P \< 0.001.
